Paarlberg Tandy E, Wiseman Scott, Trout Candace M, Kee Elizabeth A, Snyder Daniel E
Elanco Animal Health, 2500 Innovation Way, Greenfield, IN 46140, USA.
J Am Vet Med Assoc. 2013 Apr 15;242(8):1092-8. doi: 10.2460/javma.242.8.1092.
To compare safety and efficacy of spinosad and selamectin and determine effects of those products on flea allergy dermatitis (FAD) in cats.
Randomized clinical trial. Animals-211 client-owned cats.
Cats with ≥ 5 fleas evaluated at 8 veterinary clinics were allocated to receive spinosad (50 to 100 mg/kg [22.7 to 45.5 mg/lb], PO; n = 139) or selamectin (≥ 6 mg/kg [≥ 2.7 mg/lb], topically; 72) once per month. Flea comb counts and FAD scores were determined on day -1, between days 27 and 33, and between days 85 and 95 (evaluations 1, 2, and 3, respectively); day 0 was the first day of drug administration.
The most common adverse event was vomiting (14.3% and 2.4% of spinosad- and selamectin-treated cats, respectively). Evaluation 2 and 3 geometric mean flea counts for spinosad-treated cats were significantly lower than those for selamectin-treated cats. Percentage reductions in flea counts for the spinosad and selamectin groups were 97.5% and 88.8% (evaluation 2) and 99.3% and 97.7% (evaluation 3), respectively. At evaluations 2 and 3, 70.6% and 92.6% of spinosad-treated cats and 29.4% and 64.7% of selamectin-treated cats were free of fleas, respectively. Weighted FAD scores for spinosad- and selamectin-treated cats decreased 94.2% and 80.0% during the study, respectively. Spinosad tablets were successfully administered during 98.1% of treatments.
Results of this study indicated spinosad and selamectin both reduced flea counts and FAD scores for cats, although spinosad was more effective. Monthly oral administration of spinosad may be practical for treatment of flea infestations and FAD in cats.
比较多杀菌素和塞拉菌素的安全性和有效性，并确定这些产品对猫蚤过敏性皮炎（FAD）的影响。
随机临床试验。动物——211只客户拥有的猫。
在8家兽医诊所对有≥5只跳蚤的猫进行评估，将其分配接受多杀菌素（50至100mg/kg[22.7至45.5mg/lb]，口服；n = 139）或塞拉菌素（≥6mg/kg[≥2.7mg/lb]，局部用药；72只），每月一次。在第-1天、第27至33天之间以及第85至95天之间（分别为评估1、2和3）确定跳蚤梳检计数和FAD评分；第0天为给药第一天。
最常见的不良事件是呕吐（多杀菌素治疗组和塞拉菌素治疗组的猫分别为14.3%和2.4%）。多杀菌素治疗组猫在评估2和3时的几何平均跳蚤计数显著低于塞拉菌素治疗组猫。多杀菌素组和塞拉菌素组在评估2时跳蚤计数的减少百分比分别为97.5%和88.8%，在评估3时分别为99.3%和97.7%。在评估2和3时，多杀菌素治疗组分别有70.6%和92.6%的猫无跳蚤，塞拉菌素治疗组分别有29.4%和64.7%的猫无跳蚤。在研究期间，多杀菌素治疗组和塞拉菌素治疗组猫的加权FAD评分分别下降了94.2%和80.0%。98.1%的治疗过程中多杀菌素片剂给药成功。
本研究结果表明，多杀菌素和塞拉菌素均可减少猫的跳蚤计数和FAD评分，尽管多杀菌素更有效。每月口服多杀菌素可能适用于治疗猫的跳蚤感染和FAD。
